SCHEMBL11965481

SCHEMBL11965481

CC(=NOS(=O)(=O)C(F)(F)F)c1ccc(OCCCOc2ccc(C(C)=NOS(=O)(=O)C(F)(F)F)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FURIN P09958 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 2/20 0.43
PLA2G4B P0C869 2/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
TSHR P16473 2/20 0.39
TP53 P04637 1/20 0.39
PPARG P37231 3/20 0.39
PPARA Q07869 3/20 0.39
PPARD Q03181 1/20 0.39
MAPT P10636 2/20 0.39
PKM P14618 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12641556 0.95 FURIN (0.44) FURINL3MBTL1GAAPLA2G4BCA12
SCHEMBL14107991 0.89 PPARA (0.42) FURINL3MBTL1GAAPLA2G4BTSHR
SCHEMBL2607803 0.89 FURIN (0.40) FURINL3MBTL1GAAPLA2G4BCA12
SCHEMBL546603 0.84 CA12 (0.44) L3MBTL1PLA2G4BCA12CA1CA2
SCHEMBL546602 0.84 CA12 (0.44) L3MBTL1PLA2G4BCA12CA1CA2
SCHEMBL2610224 0.84 CA12 (0.44) L3MBTL1PLA2G4BCA12CA1CA2
SCHEMBL12551463 0.82 FURIN (0.40) FURINL3MBTL1GAAPLA2G4BCA12
SCHEMBL17122443 0.82 MAPT (0.46) FURINL3MBTL1CA1CA2CA9
SCHEMBL17762976 0.82 CA12 (0.40) FURINL3MBTL1GAAPLA2G4BCA12
SCHEMBL17452135 0.81 FURIN (0.43) FURINL3MBTL1GAAPLA2G4BCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8241822-B2 Halogenated oxime derivatives and the use therof as latent acids BASF SE (DE) 2012-08-14 US disclosed
US-20090042114-A1 Halogenated oxime derivatives and the use therof as latent acids YAMATO HITOSHI 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042114-A1 Halogenated oxime derivatives and the use therof as latent acids AHR, CCNT1, RTF1 FURIN 1113/4885L3MBTL1 25/4885GAA 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.